A pilot trial of immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy.
Phase 1
- Conditions
- Osteosarcoma Soft tissue sarcoma neuroblastoma Pediatric bone, soft tissue sarcoma at high risk of recurrence.
- Registration Number
- JPRN-UMIN000005312
- Lead Sponsor
- Osaka Universty
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
Not provided
Exclusion Criteria
See Japanese protocol or ask directly to us.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to progression from the end of conventional chemotherapy.
- Secondary Outcome Measures
Name Time Method